Lumipulse® G B•R•A•H•M•S PCT

The most sensitive fully automated Procalcitonin (PCT) test

Immunoreaction cartridges for in vitro diagnostic (IVD) use with a two-step sandwich immunoassay method on the LUMIPULSE G system for the quantitative determination of procalcitonin (PCT) in human serum and plasma.

The assay utilises proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes.

CE marked
Lumipulse G B•R•A•H•M•S PCT Immunoreaction Cartridges

Product number 297902

3 × 14 Tests
Lumipulse G B•R•A•H•M•S PCT Calibrators

Product number 234150

2 × 2 Concentrations
Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Details
  • Conditions of sale
  • Citations
  • Documentation
  • Related products
  • Details

    Clinical Background

    Procalcitonin (PCT) is a biomarker used for the diagnosis of bacterial infection and sepsis. The use of PCT has increased in clinical practice for improved patient management, in a variety of settings including primary care, emergency room (ER) and intensive care units (ICU).

    PCT has advantages over other biomarkers for sepsis, such as C-Reactive Protein (CRP) and white blood cell count:

    • Specificity for bacterial infection (versus inflammation in general).
    • Rapidity of rise after an insult (6 hrs).
    • Rapid decline on infection with immune control (half-life of 24 hrs).
    • Excellent correlation with severity of illness.

     

    See the LUMIPULSE G1200 working in this video:

     

     

  • Conditions of sale

    To read the end user conditions of sale for this product please visit our Resource center.

  • Citations

    The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.